We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Role of Ipsilateral Motor Cortex in Executing Movements With Increasing Demand on Precision (RIMC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01726218
Recruitment Status : Active, not recruiting
First Posted : November 14, 2012
Last Update Posted : October 11, 2017
Information provided by (Responsible Party):

March 29, 2012
November 14, 2012
October 11, 2017
May 2011
November 2016   (Final data collection date for primary outcome measure)
Define key parameters that contribute to contralesional M1 reorganization following stroke [ Time Frame: Up to six months post-stroke ]
Same as current
Complete list of historical versions of study NCT01726218 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Role of Ipsilateral Motor Cortex in Executing Movements With Increasing Demand on Precision
Enhancing Stroke Recovery Through Cortical Stimulation: The Role of the Ipsilateral Motor Cortex in Executing Movements With Increasing Demand on Precision
It is well known that the motor area of one hemisphere of the brain (motor cortex) controls the movement of the opposite of the body. However, it is not clear whether as the movement becomes more complicated, the motor cortex of both hemispheres of the brain are involved. Currently the role of the motor cortex on the same side of the body (referred to as ipsilateral motor cortex) in hand performance remains controversial. The investigators demonstrated previously in healthy subjects that transiently lowering the activity of ipsilateral motor cortex improved the performance of the opposite hand. What is not know are the mechanisms involved in these changes of behavior. Transcranial magnetic stimulation (TMS) is a device that allows the non- invasive stimulation of the brain. When brain is stimulated repetitively at a very low rate and low intensity for about 15 minutes, the stimulated brain area becomes less active. This effect lasts 10 minutes and is called a "transient artificial lesion" as it mimicks the effects of transiently interfering with the function of the stimulated brain area. In the present study the investigators will conduct experiments using repetitive TMS to downregulate the activity of the motor area as in previous experiments and measures its effect on activity of motor cortex of both hemispheres. The investigators will study healthy subjects. It would be important to understand the effects in more detail for the design of treatment strategies in patients after stroke, which will be a topic of future studies.
Not Provided
Observational Model: Case-Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
30 Stroke patients with 15 in each group based on location of stroke 50 healthy volunteers
Not Provided
  • Stroke patients
  • Healthy Control
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Active, not recruiting
December 2018
November 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria for Stroke Patients:

  • Age 18-80
  • Single cerebral ischemic infarction one month prior to entering study
  • Affecting only one hemisphere as defined by MRI of the brain
  • At the time of cerebral infarct a motor deficit of hand of Medical Research Council Scale for Muscle Strength (MRC) of < 4- of wrist and finger extension/flexion movement
  • Fugl Meyer score > 27/66 (motor domain, upper extremity)
  • Ability to operate joystick at largest target level
  • No other neurological disorder
  • No intake of Central Nervous System (CNS) active drugs
  • Ability to give informed consent
  • Ability to meet criteria of inclusion experiment
  • No major cognitive impairment

Inclusion Criteria for Healthy Subjects:

  • Age 55-80 years with no neurological or psychiatric diseases
  • Normal neurological examination
  • Normal MRI of the brain
  • Normal neuropsychological testing
  • No intake of CNS active drugs that interfere with data collection
  • No contraindication to TMS
  • Ability to give informed consent
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
R56NS070879-01 ( U.S. NIH Grant/Contract )
RIMCR56 ( Other Identifier: Other )
Not Provided
Not Provided
Cathrin Buetefisch, Emory University
Cathrin Buetefisch
  • National Institutes of Health (NIH)
  • National Institute of Neurological Disorders and Stroke (NINDS)
Principal Investigator: Cathrin Buetefisch, MD, PhD Emory University
Emory University
October 2017